The renal effects of mineralocorticoid receptor antagonists

International Journal of Cardiology

Volumn 200, Issue , 2015, Pages 20-24

  Bianchi, Stefano ^a   Batini, Valentina ^a   Bigazzi, Roberto ^a  

^a Dipartimento di Medicina Clinica Ed Unità Operativa di Nefrologia e Dialisi i   (Italy)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Hyperkalemia; Mineralocorticoid receptor antagonists; Proteinuria

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PATIROMER; PLACEBO; SPIRONOLACTONE;

CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM;

HUMANS; KIDNEY; KIDNEY DISEASES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84941996305     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.125     Document Type: Review

References (39)

1. S.A. Simpson, J.F. Tait, A. Wettstein, and et al. Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism Experientia 9 1953 333 335
2. H. Kiyomoto, K. Rafiq, M. Mostofa, and et al. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury J. Pharmacol. Sci. 108 2008 399 405
3. S. Shibata, M. Nagase, S. Yoshida, and et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1 Hypertension 49 2007 355 364
4. J.C. Aldigier, T. Kanjanbuch, L.J. Ma, and et al. Remission of existing glomerulosclerosis by inhibition of aldosterone J. Am. Soc. Nephrol. 16 2005 3306 3314
5. L. Michea, A. Villagran, A. Urzua, and et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats Hypertension 52 2008 295 300
6. J.M.C. Connell, and E. Davies The new biology of aldosterone J. Endocrinol. 186 2005 1 20
7. S.M. MacKenzie, J.M. Connell, and E. Davies Non-adrenal synthesis of aldosterone: a reality check Mol. Cell. Endocrinol. 350 2012 163 167
8. S. Arima, K. Kohagura, H.L. Xu, and et al. Non-genomic vascular action of aldosterone in the glomerular microcirculation J. Am. Soc. Nephrol. 14 2003 2255 2263
9. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int. Suppl. 3 2013 73 90
10. E. Greene, S. Kren, and T.H. Hostetter Role of aldosterone in the remnant kidney model in the rat J. Clin. Invest. 98 1996 1063 1068
11. R.J. Hene, P. Boer, H.A. Koomans, and et al. Plasma aldosterone concentration in chronic renal failure Kidney Int. 21 1982 98 101
12. S. Bianchi, R. Bigazzi, and V.M. Campese Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease Kidney Int. 70 2006 2116 2123
13. Z.Y. Quan, M. Walser, and G.S. Hill Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level Kidney Int. 41 1992 326 333
14. M. Quinkler, D. Zehnder, K.S. Eardley, and et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria Circulation 112 2005 1435 1443
15. S. Terata, M. Kikuya, M. Satoh, and et al. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama Study J. Hypertens. 30 2012 1632 1638
16. C.S. Fox, P. Gona, M.G. Larson, and et al. A multi-marker approach to predict incident CKD and microalbuminuria J. Am. Soc. Nephrol. 21 2010 2143 2149
17. R. Rocha, P.N. Chander, A. Zuckerman, and et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats Hypertension 33 1999 232 237
18. J. Du, Y.Y. Fan, H. Hitomi, and et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats Am. J. Physiol. Renal. Physiol. 297 2009 802 808
19. G. Fujisawa, K. Okada, S. Muto, and et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats Kidney Int. 66 2004 1493 1502
20. J.E. Hall, J.P. Granger, M.J. Smith Jr., and et al. Role of renal hemodynamics and arterial pressure in aldosterone "escape" Hypertension 6 1984 183 192
21. J.W. Conn, R.F. Knopf, and R.M. Nesbit Clinical characteristics of primary aldosteronism from an analysis of 145 cases Am. J. Surg. 107 1964 159 172
22. G.P. Rossi, G. Bernini, G. Desideri, and et al. Renal damage in primary aldosteronism: results of the PAPY study Hypertension 48 2006 232 238
23. V.G. Fourkiotis, O. Vonend, S. Diederich, and et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism Eur. J. Endocrinol. 168 2012 75 81
24. A. Chrysostomou, and G. Becker Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease N. Engl. J. Med. 345 2001 925 926
25. S. Bianchi, R. Bigazzi, and V.M. Campese Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study Am. J. Kidney Dis. 46 2005 45 51
26. A. Sato, K. Hayashi, and T. Saruta Effectiveness of aldosterone blockade in patients with diabetic nephropathy Hypertension 41 2003 64 68
27. A. Chrysostomou, E. Pedagogos, L. MacGregor, and et al. Double-blind, placebo-controlled study on the effects of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitory therapy, with or without an angiotensin II receptor blocker Clin. J. Am. Soc. Nephrol. 1 2006 256 262
28. A.H. Van den Meiracker, R.G.A. Baggen, S. Pauli, and et al. Spironalactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function J. Hypertens. 24 2006 2285 2292
29. M. Epstein, G.H. Williams, M. Weinberger, and et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin. J. Am. Soc. Nephrol. 1 2006 940 951
30. K. Damman, G. Navis, A.A. Voors, and et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J. Card. Fail. 13 2007 599 608
31. N.S. Anavekar, J.J. McMurray, E.J. Velazquez, and et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N. Engl. J. Med. 351 2004 1285 1295
32. P. Jose, H. Skali, N. Anavekar, and et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction J. Am. Soc. Nephrol. 17 2006 2886 2891
33. P. Rossignol, J.G. Cleland, S. Bhandari, and et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study Circulation 125 2012 271 279
34. P. Rossignol, D. Dobre, J.J. McMurray, and et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) Circ. Heart Fail. 7 2014 51 58
35. O. Vardeny, D.H. Wu, A. Desai, et al. for RALES Investigators Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure:insights from RALES (Randomized Aldactone Evaluation Study) J. Am. Coll. Cardiol. 60 2012 2082 2089
36. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin. J. Am. Soc. Nephrol. 4 2009 542 551
37. B. Pitt, S.D. Anker, D.A. Bushinsky, and et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial Eur. Heart J. 32 2011 820 828
38. B. Pitt, F. Zannad, W.J. Remme, et al. for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl. J. Med. 341 1999 709 717
39. B. Pitt, W. Remme, F. Zannad, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321